News

Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year

Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS). The therapy, STP144G, is one of four experimental treatments developed with the proprietary Sirnaomics platform. Data from these early studies are expected to eventually…

COVID-19 Triggers Relapse in Woman With aHUS: Case Study

COVID-19 might have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 36-year-old woman, according to a recent case report. Despite treatment with Soliris (eculizumab), the patient ultimately died. However, a literature review conducted by study authors revealed nine other cases of COVID-19-associated aHUS and showed…

Infection Likely Trigger of aHUS in Children, Case Report Finds

Children who develop atypical hemolytic uremic syndrome (aHUS) due to autoantibodies may have an upper airway or digestive tract infection as an initial symptom, according to a report detailing eight such pediatric aHUS cases in China. Likely treatment could involve the use of plasma exchange, corticosteroids, and immunosuppressive agents, its…